Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 14 clinical trials
Study of Nusinersen (BIIB058) in Participants With Spinal Muscular Atrophy (DEVOTE)

The primary objectives of this study are to examine the clinical efficacy of nusinersen administered intrathecally at higher doses to participants with spinal muscular atrophy (SMA), as measured

gene deletion
muscle atrophy
nusinersen
  • 168 views
  • 02 May, 2022
  • 49 locations
A Study of Nusinersen Among Participants With Spinal Muscular Atrophy Who Received Onasemnogene Abeparvovec (RESPOND)

The primary objective of this study is to evaluate the clinical outcomes following treatment with nusinersen in participants with spinal muscular atrophy (SMA) who previously received

gene deletion
nusinersen
  • 2 views
  • 15 Mar, 2022
  • 17 locations
Ultrasound-assisted vs Landmark Based Intrathecal Administration of Nusinersen

Intrathecal administration of Nusinersen, an antisense oligonucleotide capable of increasing Survival Motor Neuron protein production, has been tested in Spinal Muscular Atrophy (SMA) to improve

nusinersen
  • 4 views
  • 09 May, 2022
  • 1 location
Efficacy and Safety of Apitegromab in Patients With Later-Onset Spinal Muscular Atrophy Treated With Nusinersen or Risdiplam (SAPPHIRE)

Type 3 SMA) and are receiving an approved survival motor neuron (SMN) upregulator therapy (i.e., either nusinersen or risdiplam), to confirm the efficacy and safety of apitegromab as an adjunctive

risdiplam
nusinersen
  • 0 views
  • 08 Apr, 2022
  • 1 location
Study of the Functional Effects of Nusinersen in 5q-spinal Muscular Amyotrophy Adults (SMA Type 2 or 3 Forms) (NUSI-AD-5qSM)

. Gene therapy is now available for the management of spinal muscular atrophy and nusinersen is the first approved treatment. Nusinersen has been granted marketing authorization in France since May 30

neuromuscular diseases
spinal cord
nusinersen
deficit
  • 0 views
  • 27 Apr, 2022
  • 1 location
A Study to Evaluate Higher Dose (HD) Nusinersen (BIIB058) in Participants With Spinal Muscular Atrophy Previously Treated With Risdiplam (ASCEND)

The primary objective of this study is to evaluate motor function following treatment with HD nusinersen in participants with spinal muscular atrophy (SMA) previously treated with risdiplam.

risdiplam
gene deletion
nusinersen
  • 0 views
  • 24 May, 2022
  • 5 locations
Monitoring to the Evolution of Motor Function in SMA Type II Adults Patients Treated With SPINRAZA® (SMAII)

SPINRAZA® (Nusinersen) is the first intrathecal administered drug which was approved by the FDA to treat SMA children and adults (2016). The aim is to monitor the evolution of the Motor Function

  • 0 views
  • 10 May, 2022
  • 6 locations
Outcome Measures and Biomarkers in a Cohort of Spinal Muscular Atrophy Type III/ IV Patients (SMOB)

The "SMOB" project intends to contribute to fill the gap with reliable and operational outcome measures for type III and IV SMA. In analysing the reliability in imaging (spinal and muscular), electrophysiology analysis (MUNIX), and evaluate the evolution of respiratory function for 50 patients' cohort. The investigators would also take …

atrophy
  • 0 views
  • 22 Mar, 2022
  • 4 locations
Observational, Postmarketing Surveillance Study of Spinraza Injection (Nusinersen Sodium) (STANDARD)

The primary objective is to evaluate the safety of nusinersen sodium injection in the postmarketing setting in Korea. The secondary objective is to evaluate the effectiveness of nusinersen

spinraza
nusinersen
  • 7 views
  • 03 Mar, 2022
  • 9 locations
Non-Interventional Postmarketing Surveillance Study of Nusinersen Sodium Injection

The primary objective of this study is to evaluate the safety of nusinersen sodium injection in the postmarketing setting in China.The secondary objectives are to collect data on the efficacy

nusinersen
  • 0 views
  • 31 May, 2021
  • 9 locations